For the roughly 150,000 Americans diagnosed with colorectal cancer annually, catching the disease early — when curative resection is still possible — remains the central challenge. Most liquid biopsy platforms stumble at early stages precisely because circulating tumor DNA (ctDNA) is vanishingly scarce; a technology that can reliably read mutational signals from urine rather than tissue biopsies would fundamentally change screening accessibility and monitoring frequency.

This NPJ Precision Oncology study introduces a three-dimensional plasmonic KRAS microarray that couples blocked recombinase polymerase amplification with plasmon-enhanced fluorescence. The blocking mechanism is the key innovation: quencher-modified probes suppress wild-type DNA amplification while selectively permitting mutant templates to generate signal. A single primer-probe set per codon detects all substitution variants across KRAS codons 12/13, 61, and 146 — the clinically relevant hotspots in CRC. Analytically, the platform reached 1 femtomolar sensitivity via direct hybridization and an extraordinary 100 zeptomolar threshold after amplification, both surpassing conventional PCR and next-generation sequencing benchmarks. In a 58-patient clinical cohort, tissue, plasma, and urine samples showed 100% concordance in mutation-positive malignant cases when adequate ctDNA input was available.

Placing this in context, liquid biopsy development for CRC has accelerated sharply since the FDA clearance of Guardant360 and Shield blood tests, yet urine-based ctDNA detection remains far behind plasma-based approaches due to the additional dilution and fragmentation of cell-free DNA exiting through renal filtration. The zeptomolar sensitivity reported here, if independently replicated, would represent a meaningful leap over existing urine-based assays. Important caveats apply: the 58-patient cohort is small, the study is single-institutional, and the conspicuous absence of mutant signal in benign tumor urine samples — attributed to low ctDNA shedding — raises questions about false-negative rates in asymptomatic screening populations where tumor burden is lowest. This platform is incremental-to-notable in its analytical chemistry but requires prospective, multicenter validation before clinical translation is credible.